CV · CapsoVision, Inc
$5.91
-0.21 (-3.43%)
At close · Aug 20
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company, having evaluated the extant facts and circumstances, concluded that the facts and circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date of issuance of these financial statements. While the Company raised approximately $14 million in gross proceeds resulting from the Private Placement described in Note 1. DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE and further discussed in Note 9. COMMON STOCK, it is not probable that these funds are sufficient to fund expenditures necessary to achieve sales growth and innovation objectives. The Company intends to consummate additional capital raising activities, but there is no certainty as to such capital raising activities occurring at all, or occurring with sufficient timing or magnitude, sufficient to alleviate such substantial doubt.”View the 10-Q filed Aug 13, 2026
Market Cap
$305.04M
Shares
50.05M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.91
Open$6.12
Day$5.90–6.26
52W close$3.56–14.42
Avg vol 30d98K
Short int1.9M · 3.8% float · 21.1d
Short vol45%
Last earningsAug 13, 2026
DataJul 2025–Aug 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
−12%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
22%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
+8%
trailing
YTD return
−45%
this year
Relative strength
−4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +6 funds added
Insider flow
Accumulating
Net +$999.3K over 90 days · 50% sells
Short interest
Falling
3.82% of float · ▼ -9.3% MoM · 21.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
49 holders — mid 1-yr range
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
+15%
Y/Y
Gross margin
53%
contracting
EPS growth
+90%
Y/Y
Free cash flow
$-23.0M
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
22%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
Death cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +6 funds added
Insider flow
Accumulating
Net +$999.3K over 90 days · 50% sells
Short interest
Falling
3.82% of float · ▼ -9.3% MoM · 21.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
49 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $4
Now $6 · 22%
Range high $14
vs 200-day avg -12%
vs 50-day avg -12%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| CapsoCam Plus® used by patients | 176,000 | as of June 30, 2026 | — |
| International sales as a percentage of total revenue | 25% | the three months ended June 30, 2026 filing | — |
| New accounts growth | 21% | Full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CV
this stock
CapsoVision, Inc
|
$305.04M | -44.7% | +15.3% | — | 3.8% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.14B | -48.2% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CV | -13.0% | -10.5% | +7.7% | -10.2% | -44.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -11.0% | -13.8% | -3.5% | -12.3% | -56.5% |
Key facts
CIK
1378325
CUSIP
140935107
13F (30d)
45 filings
45 filers
Visit website
Investor relations